T-lymphoblastic lymphoma
MONDO:0044917The most frequent type of lymphoblastic lymphoma. It comprises approximately 85-90% of cases. It is more frequently seen in adolescent males. It frequently presents with a mass lesion in the mediastinum. Pleural effusions are common. (WHO, 2001)
Also known as: Precur. T-lymphoblastic lymphoma, T Lymphoblastic lymphoma, T-Lymphoblastic lymphoma, T-lymphoblastic lymphoma, precursor T Lymphoblastic lymphoma, precursor T-Lymphoblastic lymphoma, precursor T-cell Lymphoblastic lymphoma, precursor T-lymphoblastic lymphoma
1960 clinical trials for this condition and its sub-types, 32 tagged with T-lymphoblastic lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Promising drug cocktail targets tough blood cancers in kids
Disease control Recruiting nowThis study tests whether a combination of three drugs—calaspargase pegol-mknl, decitabine, and venetoclax—can help control relapsed or treatment-resistant T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LLy) in patients aged 1 month to 21 years. T…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New immunotherapy combo aims to stop relapse in young blood cancer patients
Disease control Recruiting nowThis early-phase trial tests whether adding daratumumab (an immunotherapy drug) after a stem cell transplant can safely help control high-risk T-cell acute lymphoblastic leukemia or lymphoma in children, teens, and young adults up to age 39. About 30 participants will receive the…
Phase 1 • Sponsor: New York Medical College • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Genetically modified t cells take aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of immunotherapy for people with T-cell leukemia or lymphoma that has returned. The treatment involves taking a patient's own immune cells (or cells from a past stem cell donor), adding a special receptor that targets a protein called …
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for kids with tough leukemia: targeted drugs added to chemo
Disease control Recruiting nowThis study tests whether adding dasatinib or venetoclax to standard chemotherapy can help more children with T-cell acute lymphoblastic leukemia or lymphoma achieve a deep remission. About 100 children and young adults aged 1 to 18 will receive one of these targeted drugs alongsi…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New combo therapy aims to crush T-Cell blood cancers
Disease control Recruiting nowThis phase II trial is testing a combination of chemotherapy drugs plus nelarabine in 160 people with previously untreated T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. The goal is to see if this stronger cocktail can improve remission rates and help people live …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Engineered donor cells take aim at tough T-Cell cancers
Disease control Recruiting nowThis early-phase study tests a new treatment for people with T-cell leukemia or lymphoma that has come back. The treatment uses specially trained immune cells from a healthy donor, designed to recognize and attack cancer cells carrying a marker called CD7. The goal is to see if t…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Double-Team attack: new CAR-T therapy targets two cancer markers to outsmart relapse
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy that targets two different markers on cancer cells at once, aiming to prevent the cancer from escaping treatment. It is for adults with several types of blood cancers that have come back or not responded to standard treatments. Pa…
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New trial aims to boost survival in kids with rare lymphoma
Disease control Recruiting nowThis study compares two different ways of giving methotrexate (a chemotherapy drug) to children and teens newly diagnosed with T-cell lymphoblastic lymphoma, a rare cancer of the immune system. About 200 participants will be randomly assigned to one of two treatment plans to see …
Phase 3 • Sponsor: Children's Cancer Group, China • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental cocktail aims to tackle tough blood cancers
Disease control Recruiting nowThis study tests a new drug called LP-118 combined with three existing cancer medicines (ponatinib, vincristine, and dexamethasone) in adults with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to treatment. The goal is to…
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Engineered cells take on tough blood cancer in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called OC-1, which uses a patient's own immune cells (T cells) that have been modified in a lab to recognize and attack a specific marker (CD1a) on cancer cells. The trial aims to see if this therapy is safe and can help shrink or elim…
Phase 1 • Sponsor: OneChain Immunotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for tough leukemia: capivasertib combo enters human trials
Disease control Recruiting nowThis study tests whether adding the experimental drug capivasertib to a standard treatment (venetoclax plus low-intensity chemotherapy) is safe and effective for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma that has come back or not responded to prior …
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis early-stage trial tests whether a new type of CAR T-cell therapy is safe for children and adults with T-cell leukemia or lymphoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to target a protein …
Phase 1 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Engineered immune cells take on tough childhood cancers
Disease control Recruiting nowThis study is testing a new treatment called CD7-CART01 for children whose T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma has come back or not responded to standard therapy. The treatment uses the child's own immune cells, which are modified in a lab to recognize a…
Phase 1/2 • Sponsor: Bambino Gesù Hospital and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment called CD7 CAR T-cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells or cells from a donor, which are modified to find and attack cancer cells. The …
Phase 1/2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Texting to beat leukemia: study tests if phone reminders boost chemo adherence
Symptom relief Recruiting nowThis study tests whether daily or weekly text message reminders help adolescents and young adults (ages 15-39) with acute lymphoblastic leukemia (ALL) take their oral chemotherapy medications (mercaptopurine and methotrexate) more consistently during maintenance therapy. Particip…
Sponsor: University of Chicago • Aim: Symptom relief
Last updated Jul 12, 2026 00:00 UTC
-
Massive blood cancer registry aims to unlock secrets of adult ALL
Knowledge-focused Recruiting nowThis study is a large registry that will collect medical information and biological samples from up to 10,000 adults with acute lymphoblastic leukemia (ALL) and related blood cancers. The goal is to track how patients are diagnosed, treated, and how they fare over time. By gather…
Sponsor: Goethe University • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC